Background The use of Web-based technology to facilitate self-care and communication
and effectiveness for improving patient-provider communication regarding cancer symptoms and quality of life (SxQOL) issues 9, 10 and reduced depression, anxiety, and symptom distress. [11] [12] [13] [14] However, as reviewed by Agboola, 15 findings have not been consistent across studies.
Our program of research, focused on cancer SxQOL experiences, has been conducted in 2 randomized controlled trials, the most recent being electronic self-report assessment for cancer (ESRA-C-II). 14 We evaluated the effect of Web-based, self-report assessment and monitoring, self-care instruction, and communication coaching on SxQOL during cancer treatment. Analysis of the primary outcome, Symptom
Distress Scale-15 scores, 14, 16 indicated that intervention group participants reported significantly lower symptom distress than those in the control group. Further analyses have documented the significant impact of the ESRA-C on enhancing patients' verbal reporting of symptoms 10 and the direct relationship between use of the intervention and symptom distress outcomes. 17 Our methods and secondary outcome papers have documented minimally important clinical differences for the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (QLQ-C30) used in our first randomized trial 18 and relationships between oral cancer medication adherence, depression, and demographic variables. 4 In this paper, we report a secondary analysis of psychosocial outcomes of the ESRA-C-II study by examining the effects of the intervention on depression and on social, emotional, and role functioning.
| METHODS
The detailed procedures of the ESRA-C-II trial are reported elsewhere. 14 A total of 752 ambulatory, adult (age ≥ 18 years), Englishspeaking patients diagnosed with cancer of any stage who were about to start a new cancer therapy (did not have to be first-line) were randomized to receive usual education about SxQOL topics (control) or usual education plus self-care instruction for SxQOL issues, communication coaching on how to report troublesome SxQOL to clinicians, and the opportunity to track SxQOL between clinic visits (intervention). The institutional review boards of the participating sites, comprehensive cancer centers in Seattle and Boston, approved the study protocols.
The validated ESRA-C-II questionnaires were used to screen for cancer-related SxQOL issues before treatment (T1) and at specific time points throughout therapy for both groups. The participants completed a second assessment (T2) approximately 3 to 6 weeks after starting treatment. A third assessment (T3) was scheduled 2 weeks later, and the final assessment (T4) was planned 2 to 4 weeks after treatment ended or at the next restaging visit for participants who would continue to receive treatment indefinitely (e.g., palliative therapy).
In both groups, clinicians received a 2-page, color-keyed summary depression questionnaire assigns scores of 0, 1, 2, and 3 to the response categories of "not at all," "several days," "more than half the days," and "nearly every day," respectively, over the past 2 weeks.
The PHQ-9 total score ranges from 0 to 27, where lower scores correspond to less depression. If 1 or 2 of the 9 items were not answered, then we imputed values by assigning the mean of the answered items to the missing items. 2 The QLQ-C30 has 2, 4, and 2 items for SF, EF, and RF, respectively. The functional scale summary scores were transformed to range from 0 to 100 according to published methods for version 3, 21 where higher scores correspond to a higher (better) level of function.
| STATISTICAL ANALYSIS
Our primary measures of psychosocial outcomes were the end-of-study scores. If a patient had finished treatment before T3, then T4 measures
were not administered and the T3 scores were used. All eligible, FIGURE 1 Depression communication and self-care education presented on-screen to participants scoring ≥10 on the Patient Health Questionnaire-9 (PHQ-9) measure randomly assigned patients with complete outcome data were included according to the intent-to-treat principle, regardless of whether patients utilized the provided usual education or study intervention.
The end-of-study scores, adjusted for baseline scores, for the PHQ-9
and QLQ-C30 domains were compared between study groups by using analysis of covariance. The estimated intervention effect was plotted together with a 95% confidence interval (CI). Covariates previously identified 14 as influencing symptom distress (i.e., age, clinical service in which treatment was planned when the participant enrolled in the trial [medical oncology, radiation oncology, and stem cell transplant], and working status) were adjusted in a multivariable analysis to improve precision of the intervention effect, and possible 2-way interactions were checked. Type III P-values were used to assess the overall covariate significance in each model. The change in PHQ-9 score from baseline to end-of-study was calculated, and nonparametric smoothing techniques were used to explore the impact of baseline PHQ-9 on the score change. Additionally, the intervention effect on depression was assessed on the pattern of no/mild or moderate/severe depression (PHQ9 ≥ 8) by using McNemar's test. 22 All P-values were 2-sided for which a value of <0.05 was considered statistically significant and a value of 0.05 to 0.1 was considered a nonsignificant trend. Due to the exploratory nature of this analysis, no multiple comparison adjustments were performed.
| RESULTS
Demographic and clinical characteristics of the eligible analytic sample were balanced between study groups in the original trial. 14 A total of 581 eligible participants (292 in the control and 289 in the intervention) who completed the study per protocol comprised this analytic sample. Table 1 summarizes the available sample and scores on the PHQ-9
and QLQ-C30 SF, EF, and RF scales for each time point. Missing data were negligible, and baseline scores were balanced between the 2 groups. Baseline PHQ-9 scores reflected low levels of depression overall, with means of 3.54 and 3.59 in the control and intervention groups, respectively. PHQ-9 indicates Patient Health Questionnaire-9 (range 0-27, lower = less depression); SF, QLQ-C30 social functioning; EF, QLQ-C30 emotional functioning; RF, QLQ-C30 role functioning (QLQ-C30 ranges 0-100, higher = better function). were not working. PHQ-9 indicates Patient Health Questionnaire-9; EF, QLQ-C30 emotional functioning; HSCT, hematopoietic stem cell transplant; RF, QLQ-C30 role functioning; SF, QLQ-C30 social functioning.
FIGURE 3
Effect of baseline PHQ-9 score on PHQ-9 score change between baseline and end-of-study
Our findings are consistent with other studies, showing that patients with more severe depression often respond more strongly to interventions aimed at mitigating depression. 23, 24 In an analysis of exposure to the ESRA-C intervention, working participants were more likely to use the remote intervention. 17 Not surprisingly, a similar significant relationship was found between working and better RF, as being able to work is a feature of RF as measured in the QLQ C-30.
Social functioning, or level of interference with family life and social life, was better in the intervention group and was significantly related to work status, suggesting that less symptoms/depression and working may have increased opportunities for social interactions. Although there was only a trend toward better social and role functioning in the intervention versus control group, the between-group difference of greater than 3 suggests a potentially clinically meaningful difference. found that symptom self-reporting via tablet computers among patients with advanced solid tumors improved overall HRQOL as well as anxiety/depression compared with usual care. 28 Other remote approaches, such as those that use telephone and mobile technologies, have also shown promise in improving psychosocial outcomes. 15, 29 The clinical implications of these findings are that a Web-based, self-report assessment and monitoring, self-care instruction, and communication coaching program can identify patients with depressive symptoms and provide a first step in empowering patients to manage and communicate these symptoms to their providers. A follow-up assessment for those who endorse depression is important to identify and treat patients who remain depressed and require more intensive treatment, such as pharmacotherapy or psychotherapy. 7, 8 The findings of this analysis are limited by the lack of racial, ethnic, and socioeconomic diversity in the original trial. 14 There were too few participants in each diagnostic category to stratify analysis by cancer type. Data were collected only through the end of therapy or shortly thereafter, precluding the study of longer term effects of the intervention. Depression was assessed by using self-report, so there may have been under-reporting of symptoms. Although depression was significantly lower in the intervention group compared with the control group, the effect was modest; there was likely a "floor effect" due to the non-selective nature of study inclusion and low baseline scores.
Despite baseline mean depression scores being in the "minimal" severity range, the control group's PHQ-9 score increased by 0.62 (17.5%),
whereas the intervention group's PHQ-9 score increased by 0.05 
